Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 13, 2021
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
Delaware
88-0488686
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
11388 Sorrento Valley Road
92121
San Diego
(Zip Code)
California
(Address of principal executive offices)
(858) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
HALO
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 13, 2021, Halozyme Therapeutics, Inc. (the “Company”) announced that Masaru Matsuda will step down from his position as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company, effective December 31, 2021, to pursue another opportunity. The Company intends to enter into a separation agreement with Mr. Matsuda which we expect to provide benefits consistent with those previously disclosed by the Company on its Current Report on Form 8-K filed on December 13, 2018. The Company would like to thank Mr. Matsuda for his contributions in his role during his tenure with the Company.
Effective January 3, 2022, Mark Snyder will be appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company. Mark previously served as Senior Vice President and Deputy General Counsel, Litigation at Qualcomm Incorporated.
Press Release of Halozyme Therapeutics, Inc. dated December 13, 2021
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HALOZYME THERAPEUTICS, INC.
December 13, 2021
By:
/s/ Masaru Matsuda
Name:
Masaru Matsuda, Esq.
Title:
Senior Vice President, General Counsel and Corporate Secretary
